XML 43 R31.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 5 - Commitments (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Mar. 31, 2025 | Mar. 31, 2024 | Mar. 31, 2025 | Mar. 31, 2024 | Mar. 31, 2021 | Apr. 30, 2020 | Dec. 31, 2016
The Constructs [Member] |  |  |  |  |  |  |
Maximum Contingent Obligation |  |  |  |  |  | $ 356,000,000 |
Payments for Milestone, Royalty and Sublicensing | $ 0 | $ 0 | $ 0 | $ 0 |  |  |
License Agreement Related to Pharmaceutical Products [Member] |  |  |  |  |  |  |
Maximum Contingent Obligation |  |  |  |  |  |  | $ 18,400,000
Finite-Lived License Agreements, Gross |  |  |  |  |  | $ 0 |
License Agreement to Acquire Global Rights of Pharmaceutical Product [Member] |  |  |  |  |  |  |
Maximum Contingent Obligation |  |  |  |  | $ 68,900,000 |  |
Milestone Expense | $ 25,000 |  | $ 50,000 |  |  |  |

X
- Definition Amount of maximum contingent obligation. + References No definition available. + Details
Name: | edsa_MaximumContingentObligation
Namespace Prefix: | edsa_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of milestone expense. + References No definition available. + Details
Name: | edsa_MilestoneExpense
Namespace Prefix: | edsa_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow for milestone, royalty and sublicensing, + References No definition available. + Details
Name: | edsa_PaymentsForMilestoneRoyaltyAndSublicensing
Namespace Prefix: | edsa_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_FiniteLivedLicenseAgreementsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edsa_TheConstructsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |